Abstract
The endoplasmic reticulum aminopeptidase ERAP1 regulates innate and adaptive immune responses by trimming peptides for presentation by MHC class I (MHC-I) molecules. Herein, we demonstrate that genetic or pharmacological inhibition of ERAP1 on human tumor cell lines perturbs their ability to engage several classes of inhibitory receptors by their specific ligands, including killer cell Ig-like receptors (KIR) by classical MHC-I-peptide (pMHC-I) complexes and the lectin-like receptor CD94-NKG2A by nonclassical pMHC-I complexes, in each case leading to natural killer (NK) cell killing. The protective effect of pMHC-I complexes could be restored in ERAP1-deficient settings by the addition of known high-affinity peptides, suggesting that ERAP1 was needed to positively modify the affinity of natural ligands. Notably, ERAP1 inhibition enhanced the ability of NK cells to kill freshly established human lymphoblastoid cell lines from autologous or allogeneic sources, thereby promoting NK cytotoxic activity against target cells that would not be expected because of KIR-KIR ligand matching. Overall, our results identify ERAP1 as a modifier to leverage immune functions that may improve the efficacy of NK cell-based approaches for cancer immunotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 824-834 |
| Number of pages | 11 |
| Journal | Cancer Research |
| Volume | 75 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Mar 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Medicine(all)
Cite this
ERAP1 regulates natural killer cell function by controlling the engagement of inhibitory receptors. / Cifaldi, Loredana; Romania, Paolo; Falco, Michela; Lorenzi, Silvia; Meazza, Raffaella; Petrini, Stefania; Andreani, Marco; Pende, Daniela; Locatelli, Franco; Fruci, Doriana.
In: Cancer Research, Vol. 75, No. 5, 01.03.2015, p. 824-834.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - ERAP1 regulates natural killer cell function by controlling the engagement of inhibitory receptors
AU - Cifaldi, Loredana
AU - Romania, Paolo
AU - Falco, Michela
AU - Lorenzi, Silvia
AU - Meazza, Raffaella
AU - Petrini, Stefania
AU - Andreani, Marco
AU - Pende, Daniela
AU - Locatelli, Franco
AU - Fruci, Doriana
PY - 2015/3/1
Y1 - 2015/3/1
N2 - The endoplasmic reticulum aminopeptidase ERAP1 regulates innate and adaptive immune responses by trimming peptides for presentation by MHC class I (MHC-I) molecules. Herein, we demonstrate that genetic or pharmacological inhibition of ERAP1 on human tumor cell lines perturbs their ability to engage several classes of inhibitory receptors by their specific ligands, including killer cell Ig-like receptors (KIR) by classical MHC-I-peptide (pMHC-I) complexes and the lectin-like receptor CD94-NKG2A by nonclassical pMHC-I complexes, in each case leading to natural killer (NK) cell killing. The protective effect of pMHC-I complexes could be restored in ERAP1-deficient settings by the addition of known high-affinity peptides, suggesting that ERAP1 was needed to positively modify the affinity of natural ligands. Notably, ERAP1 inhibition enhanced the ability of NK cells to kill freshly established human lymphoblastoid cell lines from autologous or allogeneic sources, thereby promoting NK cytotoxic activity against target cells that would not be expected because of KIR-KIR ligand matching. Overall, our results identify ERAP1 as a modifier to leverage immune functions that may improve the efficacy of NK cell-based approaches for cancer immunotherapy.
AB - The endoplasmic reticulum aminopeptidase ERAP1 regulates innate and adaptive immune responses by trimming peptides for presentation by MHC class I (MHC-I) molecules. Herein, we demonstrate that genetic or pharmacological inhibition of ERAP1 on human tumor cell lines perturbs their ability to engage several classes of inhibitory receptors by their specific ligands, including killer cell Ig-like receptors (KIR) by classical MHC-I-peptide (pMHC-I) complexes and the lectin-like receptor CD94-NKG2A by nonclassical pMHC-I complexes, in each case leading to natural killer (NK) cell killing. The protective effect of pMHC-I complexes could be restored in ERAP1-deficient settings by the addition of known high-affinity peptides, suggesting that ERAP1 was needed to positively modify the affinity of natural ligands. Notably, ERAP1 inhibition enhanced the ability of NK cells to kill freshly established human lymphoblastoid cell lines from autologous or allogeneic sources, thereby promoting NK cytotoxic activity against target cells that would not be expected because of KIR-KIR ligand matching. Overall, our results identify ERAP1 as a modifier to leverage immune functions that may improve the efficacy of NK cell-based approaches for cancer immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=84928699284&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928699284&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-14-1643
DO - 10.1158/0008-5472.CAN-14-1643
M3 - Article
VL - 75
SP - 824
EP - 834
JO - Journal of Cancer Research
JF - Journal of Cancer Research
SN - 0008-5472
IS - 5
ER -